Citation Impact
Citing Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review
2010
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up
2007
Second-Line Chemotherapy for Prostate Cancer: Patient Characteristics and Survival
2005
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
A view on drug resistance in cancer
2019 StandoutNature
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
2017
Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics
2009
Repopulation of cancer cells during therapy: an important cause of treatment failure
2005
Prevalence, predictors, and characteristics of off‐treatment fatigue in breast cancer survivors
2010
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
Current perspectives in muscle invasive bladder cancer
2002
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
A Brief Intervention for Fatigue Management in Breast Cancer Survivors
2008
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011
Hexylaminolaevulinate ‘blue light’ fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology
2008
Drug penetration in solid tumours
2006 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology
2008
Photodynamic therapy of cancer. Basic principles and applications
2008
Randomized controlled trial of maintaining quality of life during radiotherapy for advanced cancer
2012
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?
2004
Porphyrin‐related photosensitizers for cancer imaging and therapeutic applications
2005
A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging
2015
Gemcitabine in transitional cell carcinoma of the urothelium
2003
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
2014
Yoga for persistent fatigue in breast cancer survivors
2011
Molecular mechanisms of cisplatin resistance
2011 Standout
Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells
2006
The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer
2007
Gemcitabine in locally advanced and/or metastatic bladder cancer
2000
Immunotherapeutic Strategies for High-Risk Bladder Cancer
2007 StandoutNobel
Future strategies in the diagnosis, staging and treatment of bladder cancer
2003
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer
2015
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer
2008
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ
2005
Bladder cancer
2016 Standout
Development of Fatigue in Cancer Survivors: A Prospective Follow-Up Study From Diagnosis Into the Year After Treatment
2012
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
2005
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
2009 Standout
Satraplatin: leading the new generation of oral platinum agents
2009
Cancer immunotherapy comes of age
2011 StandoutNature
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Photodynamic therapy of cancer: An update
2011 Standout
Cancer-related fatigue—mechanisms, risk factors, and treatments
2014 Standout
Clonal evolution of chemotherapy-resistant urothelial carcinoma
2016
Bladder cancer: Epidemiology, staging and grading, and diagnosis
2005 Standout
How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature
2007
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
2005
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
2018
Defining trained immunity and its role in health and disease
2020 Standout
Review pathology in a diagnostic bladder cancer trial: Effect of patient risk category
2006
Role of bacillus Calmette–Guérin in the treatment of advanced melanoma
2011
Cancer as an evolutionary and ecological process
2006 Standout
Positive urine cytology but negative white‐light cystoscopy: an indication for fluorescence cystoscopy?
2008
Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data
2013
Satraplatin: an orally available platinum analog for the treatment of cancer
2006
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
2010
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Cancer‐Related Fatigue: State of the Science
2010
EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer
2003
Molecular biology and targeted therapies for urothelial carcinoma
2015
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
A Systematic Review of Randomized Controlled Trials for Management of Persistent Post-Treatment Fatigue in Thyroid Cancer Survivors
2014
Association Between Palliative Care and Patient and Caregiver Outcomes
2016 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study
2007
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer
2008
LONG-TERM BENEFIT OF 5-AMINOLEVULINIC ACID FLUORESCENCE ASSISTED TRANSURETHRAL RESECTION OF SUPERFICIAL BLADDER CANCER: 5-YEAR RESULTS OF A PROSPECTIVE RANDOMIZED STUDY
2005
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Bladder Cancer
2020 Standout
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Psychosocial interventions for reducing fatigue during cancer treatment in adults
2009
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
2008
Mindfulness‐based cognitive therapy reduces chronic cancer‐related fatigue: a treatment study
2010
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study
2012
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer.
2007
A Phase III, Multicenter Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Superficial Papillary Lesions in Patients With Bladder Cancer
2007
Luminescent Functional Metal–Organic Frameworks
2011 Standout
CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma
2013 StandoutNobel
Neutrophil Granulocytes Are Required for EffectiveBacillus Calmette-GuerinImmunotherapy of Bladder Cancer and Orchestrate Local Immune Responses
2006
Web-Based Tailored Education Program for Disease-Free Cancer Survivors With Cancer-Related Fatigue: A Randomized Controlled Trial
2012
Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy
2003 Standout
BODIPY dyes in photodynamic therapy
2012 Standout
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
2007
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
2014
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
REVIEW PATHOLOGY IN A DIAGNOSTIC BLADDER CANCER TRIAL: THE IMPACT OF PATIENT RISK CATEGORY
2006
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
2011
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
2005 Standout
Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity
2014
An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
2013
Works of Fred Witjes being referenced
The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer
2009
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer
1991
Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial
2007
IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDY
2005
Effects of Cognitive Behavior Therapy in Severely Fatigued Disease-Free Cancer Patients Compared With Patients Waiting for Cognitive Behavior Therapy: A Randomized Controlled Trial
2006
Satraplatin: A new treatment option for patients with hormone refractory prostate cancer
2005
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
2001
Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence Cystoscopy
2004